UCB Achieves Significant Progress in CDKL5 Deficiency Disorder Treatment
UCB, a leading global biopharmaceutical company, has recently announced encouraging results from its Phase 3 study of fenfluramine for treating CDKL5 deficiency disorder (CDD). This groundbreaking research met its primary endpoint, highlighting the positive impact of UCB's dedication to scientific innovation in the field of developmental and epileptic encephalopathies (DEEs).
The Importance of CDKL5 Deficiency Disorder
CDKL5 deficiency disorder is an ultra-rare and severe type of DEE that typically manifests in early infancy. Individuals diagnosed with CDD face a high level of unmet medical needs and currently have very few treatment options available. This condition affects approximately 1 in every 40,000 to 60,000 live births, generally presenting with symptoms starting around six weeks of age.
Details of the Phase 3 Study
The Phase 3 trial was a rigorous, randomized, double-blind, placebo-controlled study, which investigated the safety and effectiveness of adjunctive fenfluramine on 87 participants aged between one and 35 years with uncontrolled seizures linked to CDD. UCB is now eager to submit applications for regulatory approval, aiming to make this innovative treatment accessible to patients living with CDD promptly.
Promising Results and Future Directions
UCB revealed that the outcomes of the study underscore a new therapeutic pathway for individuals affected by this debilitating disorder. Fiona du Monceau, UCB's Executive Vice President of Patient Evidence, expressed gratitude towards the families and researchers involved in this vital advancement.
The primary endpoint assessment was grounded in median percent change in motor seizure frequency, comparing results from those receiving fenfluramine to the placebo group. The complete results are anticipated to be shared at an upcoming scientific meeting, which is highly awaited within the medical community.
Efficacy and Safety of Fenfluramine
Fenfluramine demonstrated excellent tolerability throughout the study, with a safety profile comparable to earlier research involving other epilepsy syndromes such as Dravet syndrome and Lennox-Gastaut syndrome. UCB is continuing its dedication to research by conducting a flexible-dose, open-label follow-up phase over 54 weeks, aimed at evaluating long-term safety and tolerability of fenfluramine for the pediatric and adult CDD population.
Regulatory Status and Accessibility
In the United States, fenfluramine oral solution is already approved for the treatment of seizures related to Dravet syndrome and Lennox-Gastaut syndrome in patients aged two and above. However, it is essential to note that there is currently no regulatory approval for the use of fenfluramine in treating CDD at this time.
About UCB
Headquartered in Brussels, Belgium, UCB is committed to transforming the lives of individuals affected by severe diseases impacting the immune and central nervous systems. With a workforce of approximately 9,000 employees spread across 40 countries and reported revenue of €6.15 billion in the past year, UCB continuously strives to innovate and lead in the biopharmaceutical industry.
Frequently Asked Questions
What is the significance of the Phase 3 study for fenfluramine?
This study marks a crucial milestone for fenfluramine as it achieved its primary and key secondary clinical endpoints, making strides towards potential approval for CDD treatment.
Who is the target population for the treatment?
The treatment is aimed at individuals diagnosed with CDKL5 deficiency disorder, a condition affecting primarily young children.
How does the study contribute to future treatments?
The results pave the way for further development and hope for better therapeutic options for patients suffering from severe epileptic disorders.
Where will more information be presented?
Complete study results are scheduled to be presented at an upcoming scientific meeting, prolonging interest in the developments surrounding this treatment.
What is UCB’s commitment to innovation?
UCB is dedicated to advancing scientific innovation and continuously invests in research to improve treatment options for rare and severe diseases.
